Gilead and MSD to advance once-weekly HIV treatment to Phase III
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
What's Your Reaction?
